Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153496 | 1.00 | POLB (0.46) | POLBMAPK1ADAMTS4ADAMTS5SMN1; SMN2 | |
| SCHEMBL17865732 | 1.00 | POLB (0.46) | POLBMAPK1ADAMTS4ADAMTS5SMN1; SMN2 | |
| SCHEMBL17865746 | 0.87 | ACHE (0.44) | POLBLMNAMEN1USP2ALDH1A1 | |
| SCHEMBL17865775 | 0.87 | ACHE (0.44) | POLBLMNAMEN1USP2ALDH1A1 | |
| SCHEMBL20153502 | 0.87 | ACHE (0.44) | POLBLMNAMEN1USP2ALDH1A1 | |
| SCHEMBL17865731 | 0.86 | L3MBTL1 (0.50) | MAPK1SMN1; SMN2GAALMNAMAPT | |
| SCHEMBL17969615 | 0.86 | L3MBTL1 (0.50) | MAPK1SMN1; SMN2GAALMNAMAPT | |
| SCHEMBL20153491 | 0.86 | L3MBTL1 (0.50) | MAPK1SMN1; SMN2GAALMNAMAPT | |
| SCHEMBL19541331 | 0.83 | ADAMTS5 (0.48) | ADAMTS5LIPE | |
| SCHEMBL19521228 | 0.83 | ADAMTS5 (0.48) | ADAMTS5LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | claimed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | claimed |
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| EP-3036219-A2 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | ADH1A, ADH1C, SLC10A1 | POLB 2432/4885MAPK1 3479/4885ADAMTS4 3731/4885 |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | SLC1A2, SLC7A11, SLC18A2 | POLB 1829/4885MAPK1 4728/4885ADAMTS4 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.